A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

scientific article published on 16 May 2017

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1085422047
P356DOI10.1007/S11060-017-2469-X
P698PubMed publication ID28510787

P2093author name stringMinesh Mehta
Jeffrey Raizer
Kenji Muro
James Chandler
Irene Helenowski
Robert Levy
Priya Kumthekar
Maryanne Marymont
Sean Grimm
Katie McCarthy
Leanne Fountas
P2860cites workEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialQ29547224
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.Q30447832
Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cellsQ34128180
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytomaQ34498352
Mechanisms of action of arsenic trioxide.Q34525425
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.Q36163603
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growthQ36545726
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapiesQ36693019
Understanding the role of tumor stem cells in glioblastoma multiforme: a review articleQ37790294
Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse modelsQ37856463
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideQ38390616
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomasQ39766734
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxideQ40520929
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targetingQ43068233
Arsenic reverses glioblastoma resistance to mTOR-targeted therapiesQ43128991
Response criteria for phase II studies of supratentorial malignant gliomaQ44781447
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomasQ48415956
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant gliomaQ48605897
Bevacizumab for newly diagnosed glioblastomaQ87922532
P433issue3
P921main subjectphase II clinical trialQ42824440
P304page(s)589-594
P577publication date2017-05-16
P1433published inJournal of Neuro-OncologyQ15752119
P1476titleA phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas
P478volume133

Reverse relations

cites work (P2860)
Q52646455A highlight on Sonic hedgehog pathway.
Q57485029A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system
Q64057935Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer
Q93163558Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
Q52584360Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2.
Q47435333Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation
Q55456713Do Selected Blood Inflammatory Markers Combined with Radiological Features Predict Proliferation Index in Glioma Patients?
Q61445010WZY-321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy-associated manner

Search more.